Results 51 to 60 of about 2,479 (207)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Journal of Pain Research, 2023
Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department ...
Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, Koga N   +8 more
doaj  

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

The Journal of Headache and Pain, 2021
Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine.
Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka, Hans-Christoph Diener   +8 more
doaj   +1 more source

Clinical practice in prevention of migraine with calcitonin-gene related peptide monoclonal antibodies: real-world evidence [PDF]

, 2022
Introducción: Los anticuerpos monoclonales (mAbs) del péptido relacionado con el gen de la calcitonina (CGRP) son un novedoso tratamiento para prevenir la migraña crónica y la episódica de alta frecuencia.
Castaño-Amores, Celia, Nieto-Gómez, Pelayo, Nieto-Sánchez, María Teresa, Álvarez-Sánchez, Raquel   +3 more
core   +2 more sources

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

Cureus, 2022
Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment.
Kawamura, Shin, Katsuki, Masahito, Kashiwagi, Kenta, Koh, Akihito   +3 more
openaire   +2 more sources

Competing treatments for migraine: a headache for decision-makers [PDF]

, 2023
BACKGROUND: Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year.
Duncan, C, Madan, J, Matharu, M, Mistry, H, Naghdi, S, Underwood, M   +5 more
core  

Comparative Clinical Efficacy Study between Erenumab and Fremanezumab

Medical Sciences Forum, 2022
A retrospective comparative study was conducted to compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives for ...
Raquel Fresquet, Lucia Sopena, Jose Manuel Vinuesa, Aritz Merchan, Lucía Cazorla, Maria Perez, Alberto Frutos, Mercedes Arenere, Maria del Puerto Pardo, Maria de los Ángeles Allende, Tránsito Salvador   +10 more
doaj   +1 more source

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients [PDF]

, 2023
Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence ...
Adell Ortega, Vanesa, Alpuente, Alicia, Belvís, Robert, Berrocal-izquierdo, Nuria, Camiña Muñiz, Javier, Campdelacreu, Jaume, Campoy, Sergio, Cano Sánchez, Luis Miguel, Caronna, Edoardo, Castro-sánchez, María Victoria, Díaz-insa, Samuel, Echavarría Íñiguez, Ana, García Alhama, Jessica, García-sánchez, Sonia María, García-ull, Jésica, Gil Luque, Sendoa, Gonzalez-martinez, Alicia, Huerta-villanueva, Mariano, López Bravo, Alba, Molina Martínez, Francisco José, Morollón, Noemí, Muñoz-vendrell, Albert, Mínguez-olaondo, Ane, Navarro Pérez, María Pilar, Nieves Castellanos, Candela, Olivier, Marina, Pozo-rosich, Patricia, Prat, Joan, Quintas, Sonia, Rubio-flores, Laura, Ruibal Salgado, Marta, Santos Lasaosa, Sonia, Torres-ferrus, Marta   +32 more
core   +1 more source

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Journal of Pain Research, 2023
Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department ...
Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, Koga N   +8 more
doaj  

The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis [PDF]

, 2023
OBJECTIVE: While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs.
Deligianni, Christina I., Gil-Gouveia, Raquel, Jassal, Tanvir, Lampl, Christian, Maassen van den Brink, Antoinette, Reuter, Uwe, Sacco, Simona, Sanchez-Del-Rio, Margarita, Uluduz, Derya, Versijpt, Jan, Zeraatkar, Dena   +10 more
core   +3 more sources

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine

Pain and Therapy, 2020
Migraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between ...
Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett, Omar Viswanath   +12 more
doaj   +1 more source